A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 137-144

  Infante, Jeffrey R ^a,b   Jones, Suzanne F ^a,b   Bendell, Johanna C ^a,b   Greco, F Anthony ^a,b   Yardley, Denise A ^a,b   Lane, Cassie M ^a   Spigel, David R ^a,b   Hainsworth, John D ^a,b   Burris Iii, Howard A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

Author keywords

Capecitabine; Hand foot skin reaction; Pharmacokinetics; Sorafenib

Indexed keywords

CAPECITABINE; FLUOROURACIL; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BENZENESULFONATES; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES;

EID: 84856719778     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1674-0     Document Type: Article

References (21)

1. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
2. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
3. A Jemal T Murray E Ward, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30 15661684 10.3322/canjclin.55.1.10 (Pubitemid 40310185)
4. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 15466206 10.1158/0008-5472.CAN-04-1443 1:CAS:528: DC%2BD2cXotFalsbk%3D (Pubitemid 39331023)
5. Xeloda® Tablets package insert. New Jersey Roche Laboratories, Inc.:April 2006
6. E Bajetta G Procopio L Celio, et al. 2005 Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women J Clin Oncol 23 2155 2161 15710946 10.1200/JCO.2005.02.167 1:CAS:528:DC%2BD2MXjsVyiu78%3D (Pubitemid 46218707)
7. M Theodoulou U Dugan K Feigin, et al. 2008 A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study J Clin Oncol 26 66s 10.1200/JCO.2007.12.3604 Abstract #1101
8. J Baselga JGM Segalla H Roche, et al. 2009 SOLTI-0701: a double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients with locally advanced breast cancer Eur J Cancer (ECCO-EMSO) 7 3 4
9. A Awada T Gil N Whenham, et al. 2009 Phase I dose escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors Eur J Cancer (EORTC-NCI-AACR) 4 33 (Abstract #98)
10. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
11. ME Lacouture S Wu C Robert, et al. 2008 Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib Oncologist 13 1001 1011 18779536 10.1634/theoncologist.2008-0131 1:CAS:528:DC%2BD1cXhtlaksrrP
12. SM Gressett BL Stanford F Hardwicke 2006 Management of hand-foot syndrome induced by capecitabine J Oncol Pharm Pract 12 131 141 17022868 10.1177/1078155206069242 1:CAS:528:DC%2BD28XhtlSksrfL (Pubitemid 44696441)
13. DG Haller J Cassidy SJ Clarke, et al. 2008 Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 26 2118 2123 18445840 10.1200/JCO.2007.15.2090 1:CAS:528:DC%2BD1cXms1Ort7w%3D
14. EG Chiorean CJ Sweeney CF Verschraegen, et al. 2007 Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study ASCO Meeting Abstracts 26 3562
15. Nexavar® Tablets Package Insert. New Jersey Bayer HealthCare Pharmaceuticals, Inc.:2009
16. C Sweeney C Verschraegen G Chiorean, et al. 2007 A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors J Clin Oncol 25 18 3592
17. KD Miller LI Chap FA Holmes, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 15681523 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D (Pubitemid 46224178)
18. LB Saltz S Clarke E Diaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
19. HS Hochster LL Hart RK Ramanathan, et al. 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 3523 3529 18640933 10.1200/JCO.2007.15.4138 1:CAS:528: DC%2BD1cXpvVWmtLs%3D
20. P Bhargava B Esteves DA Nosov, et al. 2009 Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC) J Clin Oncol (ASCO Meeting Abstract) 27 5032
21. Sharma S, Abhyankar V, Burgess RE et al (2009) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol